SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Meridian Medical Technologies, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
COMMON STOCK, $.010 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
- --------------------------------------------------------------------------------
(CUSIP Number)
Robert G. Foster, 4 Milk Street, Portland, ME 04101
- --------------------------------------------------------------------------------
(Name, Address, Telephone Number of Persons Authorized to Receive Notices and
Communications)
April 12, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of Pages
<PAGE>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
Commonwealth Bioventures V Limited Partnership
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ]
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
- --------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH 319,565
------------------------------------------------
8 SHARED VOTING POWER
0
------------------------------------------------
9 SOLE DISPOSITIVE POWER
319,565
------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
319,565
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.67%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN*
- --------------------------------------------------------------------------------
<PAGE>
ITEM 1. SECURITY AND ISSUER. The class of securities to which this Schedule
relates is Common Stock, $.10 par value of Meridian Medical Technologies, Inc.,
a Delaware corporation (the "Issuer"). The address of the principal executive
office of the Issuer is:
Meridian Medical Technologies, Inc.
10240 Old Columbia Road
Columbia, Maryland 21046
ITEM 2. IDENTITY AND BACKGROUND.
(a) The reporting person's name is Commonwealth BioVentures V Limited
Partnership, a Delaware limited partnership with a principal business and office
address of 4 Milk Street, Portland, ME 04101. The reporting person's principal
business is that of a venture capital fund.
During the last five years, the reporting person has not been
convicted in a criminal proceeding (excluding traffic violations and similar
misdemeanors). During the last five years, the reporting person has not been a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding has been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. This item is not
applicable to the reporting person.
ITEM 4. PURPOSE OF TRANSACTION. This item is not applicable to the reporting
person.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) The number of securities of the Issuer the reporting person may be
deemed to beneficially own is 319,565. Of those, 129,914 represent securities
which the reporting person may be deemed to have the right to acquire within 60
days. This aggregate represents approximately 10.67% of the Issuer's outstanding
class of such securities.
(b) The reporting person has the sole power to vote and the sole power to
dispose of 319,565 shares of the Issuer's securities.
(c) The reporting person sold 20,000 shares of the Issuer's Common Stock
in a public sale between April 12, 1999 and April 19, 1999. Specifically, the
reporting person sold 3,300
<PAGE>
shares on April 12, 1999 at $4.125 per share; 10,000 shares on April 14, 1999 at
$4.00 per share; and 6,700 shares on April 19, 1999 at $4.00 per share.
(d) Not applicable.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER. This item is not applicable to the reporting person.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. This item is not applicable to the
reporting person.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
COMMONWEALTH BIOVENTURES
V LIMITED PARTNERSHIP
By: Bioventure Partners Limited
Partnership, its general partner
By: Commonwealth BioVentures, Inc., its
general partner
5/14/99 By: /s/ Robert G. Foster
--------------------- ------------------------------------
Date Robert G. Foster, President
